US-based Thermo Fisher Scientific has launched Gibco CTS Detachable Dynabeads, its next generation platform of Dynabeads for clinical trial and commercial use in cell therapy production.

The CTS Detachable Dynabeads’ active release mechanism, claimed to be the first of its kind, uses a release buffer to allow users to actively detach Dynabeads from a target cell at any time in the manufacturing process.

This enables the Dynabeads to offer high cell purity, yield, and viability while assisting in the reduction of manufacturing costs, according to the biotechnology company.

Thermo Fisher said that these manufacturing advantages can help cell therapy researchers treat more patients rapidly, especially those with difficult-to-treat conditions like blood cancers.

CTS Detachable Dynabeads also provides scalability, automation compatibility, and process flexibility via its unique active release mechanism.

This functionality is said to allow users take better control of their process with the ability to consistently deliver target cells with the desired properties for their therapy. The platform also optimises cell recovery, phenotypic, and viability for downstream workflow steps.

The American biotechnology firm said that these advantages will help cell therapy manufacturers to scale production while preserving performance consistency.

The Gibco CTS Detachable Dynabeads platform is intended to work within the company’s modular, closed, and automated cell therapy manufacturing workflow.

In combination with the firm’s Gibco Cell Therapy Systems (CTS) portfolio of products, the platform enables users to accelerate their manufacturing workflow by reducing the time required for steps after cell isolation. The portfolio includes the Gibco CTS DynaCellect Magnetic Separation System.

Thermo Fisher Scientific vice president and cell culture and cell therapy general manager Tiffani Manolis said: “Our CTS Detachable Dynabeads platform represents a new generation of cell therapy isolation and activation products that prioritise patient quality and safety while also creating greater workflow control for our customers.

“These advancements are one step in the process of helping our customers commercialise affordable therapies faster and potentially save more lives.”

The CTS Detachable Dynabeads CD3/CD28 Kit is the first product available on the new platform. It is designed to assist manufacturers in isolating and actively targeting T cells in a single step.